Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + Famitinib in R/M NPC
NCT05020925Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in nasopharyngeal carcinoma (NPC), sponsored by Hengrui. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05020925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020925.